Global Mpox Vaccine Stockpile Launches; GeoVax Positions GEO-MVA for Phase 3
GOVX is trading near its 52-week low of $0.46 (4.7% above the low).
Summary
A new global mpox vaccine stockpile funded by Gavi and coordinated through the ICG launched on August 27, with WHO announcing it September 2. GeoVax welcomes the initiative and details GEO-MVA readiness: GMP product manufactured, EMA Scientific Advice supporting an expedited immune-bridging pathway, and CRO/site engagement advancing for a ~500-participant pivotal study planned for Q4 2026. The company also highlights next-gen MVA-X single-dose vaccine and scalable manufacturing efforts. This follows the August 6 news of completed manufacturing and regulatory milestones for GEO-MVA, and the August 24 outreach on its Ebola portfolio. The stockpile creates a potential procurement channel for GEO-MVA, but no supply agreement or funding is announced. Watch for the Phase 3 trial initiation in Q4 2026.
At the time of this announcement, GOVX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.46 to $18.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.